secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001140361-24-008937
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 1.02, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed Q4 net loss $186M; ARIKAYCE FY rev $305M (+24%), beats guidance; ASPEN data on track Q2 2024
--------------------------------------------------------------------------------

- Total revenue $83.7M in Q4 2023 (+41% YoY); full-year 2023 revenue $305.2M (+24% YoY), exceeding guidance.
- Net loss $186.1M in Q4 ($1.28/share) and $749.6M for FY2023 ($5.34/share); R&D spend $571M in FY2023.
- Cash, equivalents and marketable securities $780.4M as of Dec 31, 2023; new $500M ATM agreement with Leerink entered Feb 22, 2024.
- ARIKAYCE global revenue guidance for 2024 reiterated at $340M-$360M (15% YoY growth at midpoint).
- Topline data from Phase 3 ASPEN study (brensocatib) expected Q2 2024; Phase 2 TPIP PH-ILD data also expected Q2 2024 ahead of ASPEN.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124008937/0001140361-24-008937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124008937/ef20022087_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-008937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer